Literature DB >> 3276823

The characteristics and outcome of patients with late relapse acute myelogenous leukemia.

H M Kantarjian1, M J Keating, R S Walters, K B McCredie, E J Freireich.   

Abstract

The characteristics and outcome of 58 patients with acute myelogenous leukemia (AML) who experienced relapse after a first remission duration longer than 18 months (late-relapse AML) were analyzed and compared with those of 278 patients with earlier relapses. Late-relapse AML was associated with a lower incidence of antecedent hematologic disorder, leukocytosis, and elevated creatinine and lactic acid dehydrogenase (LDH) levels. A favorable karyotype (inversion of chromosome 16; translocations between chromosomes 8 and 21, or 15 and 17) was more frequent in patients whose first remission was 12 months or longer compared with less than 12 months (30% v 10%; P less than .0001). An unfavorable karyotype (chromosome 5 and 7 abnormalities, trisomy 8, other changes) was more frequent in the latter category (16% v 42%; P less than .0001). Thirty-seven of the 58 patients (64%) with late-relapse AML achieved complete remission (CR). The incidence of CR increased significantly with an increased first remission duration from less than 12, 12 to 18, and greater than 18 months (17% v 41% v 64%; P less than .0001), while the incidence of resistant disease was significantly lower (59% v 36% v 19%; P less than .0001). When effective antileukemic regimens were considered, remission rates were also significantly increased by the duration of first remission (24% v 48% v 72%; P less than .001). Compared with patients with earlier relapse, those with late-relapse AML had a longer median survival from salvage therapy (3.5 v 12 months; P less than .01), and longer median second remission durations (3.5 v 11 months; P less than .01). We conclude that late-relapse AML has unique clinical, cytogenetic, and prognostic characteristics, and remains extremely sensitive to chemotherapy with a potential cure fraction. The duration of first remission is an important prognostic parameter in AML relapse and may be useful in the design and analysis of future salvage programs.

Entities:  

Mesh:

Year:  1988        PMID: 3276823     DOI: 10.1200/JCO.1988.6.2.232

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

1.  Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.

Authors:  Carolina Reyes; Nicole M Engel-Nitz; Stacey DaCosta Byfield; Arliene Ravelo; Sarika Ogale; Tim Bancroft; Amy Anderson; May Chen; Matthew Matasar
Journal:  Oncologist       Date:  2019-02-26

2.  Prognosis of patients with core binding factor acute myeloid leukemia after first relapse.

Authors:  Saiko Kurosawa; Shuichi Miyawaki; Takuhiro Yamaguchi; Heiwa Kanamori; Toru Sakura; Yukiyoshi Moriuchi; Fumiaki Sano; Takeshi Kobayashi; Atsushi Yasumoto; Kazuo Hatanaka; Masamitsu Yanada; Yuichiro Nawa; Jin Takeuchi; Yukinori Nakamura; Shin Fujisawa; Hirohiko Shibayama; Ikuo Miura; Takahiro Fukuda
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

3.  Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.

Authors:  Inaam Bashir Hassan; Jorgen Kristensen; Khalid Al Qawasmeh; Arif Alam
Journal:  Int J Hematol       Date:  2018-06-27       Impact factor: 2.490

4.  Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients.

Authors:  Justin M Watts; Xin Victoria Wang; Mark R Litzow; Selina M Luger; Hillard M Lazarus; Peter A Cassileth; Hugo F Fernandez; Dan Douer; Lynette Zickl; Elisabeth Paietta; Jacob M Rowe; Martin S Tallman
Journal:  Leuk Res       Date:  2014-06-02       Impact factor: 3.156

5.  High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

Authors:  Richard M Stone; Barry Moser; Ben Sanford; Philip Schulman; Jonathan E Kolitz; Steven Allen; Wendy Stock; Ilene Galinsky; Ravi Vij; Guido Marcucci; David Hurd; Richard A Larson
Journal:  Leuk Res       Date:  2010-08-04       Impact factor: 3.156

6.  Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia.

Authors:  Patrick D Bhola; Brenton G Mar; R Coleman Lindsley; Jeremy A Ryan; Leah J Hogdal; Thanh Trang Vo; Daniel J DeAngelo; Ilene Galinsky; Benjamin L Ebert; Anthony Letai
Journal:  J Clin Invest       Date:  2016-09-06       Impact factor: 14.808

Review 7.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 8.  Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.

Authors:  Jeffrey C Bryan; Elias J Jabbour
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

9.  Highly refractory acute myeloid leukemia.

Authors:  Wolfgang Füreder; Martin Filipits; Wolfgang R Sperr; Birgit Kainz; Ulrich Jäger; Christa Fonatsch; Ilse Schwarzinger; Oskar A Haas; Robert Pirker; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

10.  Monitoring of acute myeloid leukemia by flow cytometry.

Authors:  Wolfgang Kern; Susanne Schnittger
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.